WO2003045407A1 - Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation - Google Patents
Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation Download PDFInfo
- Publication number
- WO2003045407A1 WO2003045407A1 PCT/CN2001/001591 CN0101591W WO03045407A1 WO 2003045407 A1 WO2003045407 A1 WO 2003045407A1 CN 0101591 W CN0101591 W CN 0101591W WO 03045407 A1 WO03045407 A1 WO 03045407A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- traditional chinese
- chinese medicine
- extract
- weight
- medicine composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating nasal congestion and headache, and a preparation method thereof.
- the nasal congestion caused by wind chills and migraine headaches are medical diseases with a high incidence in winter and spring.
- the pathogenesis is that the head of the wind evil and cold is upset, the air of Qingyang is blocked, the qi and blood stagnate, and the headache is blocked by the obstruction of the collaterals; .
- Amaranth has a pungent taste, and it belongs to the stomach, large intestine, and lung meridian.
- Xin Neng San can do it, Bai Zhi Xin Wen walks away, good at the head to dispel wind and cold, Chuanxiong taste Wei Xin, return to the liver, gallbladder, pericardial meridian, with blood circulation Qi, pain relief.
- Amaranth contains ingredients such as imperatorin, isoimperatorin, berberine, and berberine, which are the main effective ingredients of bleach, analgesic, sedative, antibacterial and anti-inflammatory.
- Ligusticum chuanxiong contains phenolic substances such as ligustrazine, alkaloids, and ferulic acid. It is the main active ingredient of Chuanxiong to promote blood circulation and relieve pain.
- the purpose of the present invention is to provide a traditional Chinese medicine composition which has the effect of treating nasal congestion, headache, fast absorption, good curative effect, no side effects, convenient taking and its preparation method; another object of the present invention is to provide a new pharmaceutical use of the above composition .
- the relative density of the thick paste under C is not less than 1. 30, and it is extracted by refluxing with 10 to 16 times the amount of ethanol for 1 hour, and filtered to obtain the filtrate.
- the oil residue is added with 10 to 15 times of ethanol to heat and reflux to extract 1-2 Then, it was filtered to obtain a filtrate.
- the filtrates were combined and concentrated under reduced pressure to a thick paste having a relative density of not less than 1.
- each 0.54g medicament contains equivalent 1.41g ⁇ ⁇ .
- the oral dosage of the capsules prepared by the present invention is 3 capsules once, 3 times per day.
- the disintegration time of the capsules of the present invention after taking is 4-6 minutes, and the imperatorin content in the finished product is 0.517-0.579%.
- the capsule of the invention has fast onset, good curative effect, small oral dosage, and convenient administration.
- the experimental study has shown that the medicine of the present invention has the exact curative effect, and the preparation method of the medicine of the present invention also optimizes the amount of the raw medicine contained in the medicine.
- the raw medicine content of the medicine extract of the present invention can reach 17 g per liter.
- the medicine of the present invention has been researched by the Tianjin Institute of Materia Medica of the State Administration of Medicine and has been shown to have bacteriostatic, anti-inflammatory, analgesic, improving microcirculation and reducing blood viscosity.
- the extract of the present invention is a brown-yellow liquid with a content of 8 g / liter (equivalent to the amount of crude drugs, the same applies hereinafter).
- the batch number 930821 was provided by Lianyungang Kangyuan Pharmaceutical Co., Ltd. It was stored in a water tank and diluted with distilled water to the required concentration before testing for animal testing. Test animal:
- Kunming mice 140 males, weighing 18 to 22 g, both male and female.
- the animals are kept in a 26 ° C 2 ° C centrally controlled observation room, and the animal qualification certificate is "Jinfa 001"
- Staphylococcus aureus (6538), hemolytic streptococcus B (32210), and Pseudomonas aeruginosa (27853) were provided by the Tianjin Center for Disease Control.
- the golden yellow Staphylococcus, B-hemolytic streptococcus and P. aeruginosa strains were cultured with the corresponding culture broth and counted for viable bacteria, and diluted to a concentration of cfu / ml for use.
- the minimum concentration of the test drug contained in the sterile growth plate was the minimum bacteriostatic concentration.
- Pinggu without test drugs was set as a negative control.
- the results showed that the drug had antibacterial effects on Staphylococcus aureus, Streptococcus B and Pseudomonas aeruginosa (see Table 1).
- the minimum inhibitory concentrations were 0.29 / ml, 0.04g / ml and 0.5g / ml.
- mice weighing 19 to 22 g were randomly divided into groups of 10 mice.
- a model control group was set up to test the extracts of the present invention in three dose groups of 8 g / kg, 4 g / kg, and 2 g / kg. Take the medicine once for 3 consecutive days.
- the blank control group was given an equal volume of distilled water. 30 minutes after the last administration, the left ear shell of each mouse was coated with 3% croton oil 0.02 ml to cause inflammation. After 2 hours, the mice were sacrificed, two ears were cut off, and 0.7 cm ear pieces were washed down, accurately weighed.
- mice of 19-22g were randomly divided into groups of 10 mice, half male and half female. A blank control group and a test drug were set.
- the extract of the invention was 8g / kg, 4g / kg ⁇ 2g / kg ⁇ - ⁇ ⁇ J quantity group. Mice of each group were given the corresponding medicinal solution by gavage once, and the blank control group was given an equal volume of distilled water.
- mice in each group were tested for tail flicking time before and 30 minutes, 60 minutes, and 120 minutes after dosing (that is, from the lower end of the tail immersed in 55 ° C soil 0.5 C constant temperature water bath to The tail of the mouse is lifted and shaken), and the tail flicking time of the mouse is subtracted from the tail flicking time before the administration to extend the tail flicking time of the mouse.
- the T test is compared with the blank control group. The results showed that the drug was administered to the stomach once, and the three doses could significantly prolong the heat-induced pain in mice. Compared with the blank control group, the tail flick time is significantly different (P ⁇ 0.01, P ⁇ 0.001).
- the test results show that the extracts of 8g / kg, 4g / kg and 2g / kg have obvious Analgesic effect (see Table 3).
- Extract of the invention 8. 0 10 1. 110 ⁇ 0. 870 ⁇ ⁇ . 626 *** 0. 866 ⁇ 0. 953 JO. 553 ***
- Extract of the invention 4. 0 10 1. 114 ⁇ 0. 551 iQ. 636 ** 0. 506 JO. 732 0. 551 «. 408 **
- Extract of the invention 2. 0 10 1. 055 ⁇ 0. 420 ⁇ 0. 333 ** 0. 656 3 ⁇ 4. 623 * 0. 579 ⁇ 0. 432 **
- Healthy rabbits both male and female, were randomly divided into a model group and test drug extracts of the present invention (4g / kg and 2g / kg) in two dose groups, 8-10 in each group, administered orally.
- test drug extracts of the present invention 4g / kg and 2g / kg
- sodium pentobarbital was anesthetized, and the microcirculation of the conjunctiva of the rabbit was observed 80 times with a stereo dissecting microscope.
- the extract of the present invention has obvious antibacterial effects on Staphylococcus aureus, Streptococcus B type and Pseudomonas aeruginosa, and the minimum concentration of the bacillus is 0.2g / ml, 0.04g / ml and 0.58 / ml.
- Intragastric administration of 2g / kg, 4g / kg and 8g / kg doses can significantly inhibit swelling of the auricles of mice and prolong the tail flick time of mice caused by warm pain.
- the medicine of the present invention has certain anti-inflammatory and analgesic effects.
- Intragastric administration of 4g / kg and 2g / kg doses can significantly inhibit and improve microcirculation disturbance in rabbits caused by high molecular dextran, reduce blood viscosity, and promote blood circulation.
- the pharmacodynamic test proves that the extract of the present invention has pharmacological effects of bacteriostatic, anti-inflammatory, analgesic, improving microcirculation, and reducing blood viscosity.
- This study provides a scientific basis for the clinical application of the drug.
- the clinical study of the medicine of the present invention shows that it has definite curative effect on treating nasal congestion and headache.
- the soft gelatin capsule made by the present invention has been clinically verified by Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing Traditional Chinese Medicine Hospital, and Subei People's Hospital on 100 cases of cold headache, and the cure rate is 77%, and the total effective rate is 96%.
- TCM diagnostic criteria Headaches are episodic, and they occur frequently in the frontotemporal, hindbrain, nasal congestion, and wind and chills; the symptoms are more acute, and there may be inducements such as cold and fatigue before the onset of illness.
- Treatment method The treatment group took the capsules of the present invention orally 3 capsules each time, 3 times a day. Three days is a course of treatment. Observe one course of treatment. During the observation period, other similar drugs are prohibited.
- each index scoring standard first calculate the integral value of each index before treatment, and then calculate the ratio of post-treatment and pre-treatment points, and use this ratio to determine the efficacy.
- the clinical recovery score ratio is between 0 and 0.2
- Example 2 Take 1500 grams of Ligusticum chuanxiong and 375 grams of Ligusticum chuanxiong; pulverize Baiji and Ligusticum chuanxiong into lumps.
- the crushing degree of the medicinal material is 0.3cm in diameter, add 8 times water, extract volatile oil, and concentrate the water extract to a thick paste with a relative density of not less than 1.342 (60 * C), extract 16 times the amount of ethanol under reflux for 1 hour, filter to obtain the filtrate; extract the oil residue and add 14 times of ethanol to heat and reflux for 2 times, and filter to obtain the filtrate; combine the filtrate and concentrate under reduced pressure to Thick paste with a relative density of not less than 1.30 (60 ° C), dried under vacuum), pulverized into powder, added volatile oil, milled with a suitable amount of vegetable oil in a colloid mill, and pressed it into a soft gel shell to obtain The grain content weighed 0.54 g, which was equivalent to 1.41 g of crude drug.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/497,287 US20050084552A1 (en) | 2001-11-29 | 2001-11-29 | Pharmaceutical composition of chinese herbs for treating snuffle, headache and the use thereof |
AU2002221510A AU2002221510A1 (en) | 2001-11-29 | 2001-11-29 | A pharmaceutical composition of chinese herbs for treating snuffle, headache and the use thereof |
PCT/CN2001/001591 WO2003045407A1 (fr) | 2001-11-29 | 2001-11-29 | Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2001/001591 WO2003045407A1 (fr) | 2001-11-29 | 2001-11-29 | Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003045407A1 true WO2003045407A1 (fr) | 2003-06-05 |
Family
ID=4574897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/001591 WO2003045407A1 (fr) | 2001-11-29 | 2001-11-29 | Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation |
Country Status (3)
Country | Link |
---|---|
US (1) | US20050084552A1 (zh) |
AU (1) | AU2002221510A1 (zh) |
WO (1) | WO2003045407A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716295B (zh) * | 2012-06-28 | 2013-12-04 | 陈慧婷 | 治疗胁痛的白芍中药制剂及制备方法 |
CN107812288B (zh) * | 2017-11-29 | 2023-10-27 | 湖南气和医疗科技有限公司 | 用于呼吸道疾病的气味康复训练装置及配套使用的中药包 |
CN109731023A (zh) * | 2019-02-15 | 2019-05-10 | 浙江安吉开元美林中医药健康产业有限公司 | 一种细辛外用膏药及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1116545A (zh) * | 1995-04-07 | 1996-02-14 | 唐道臣 | 醒脑止痛增智粉剂 |
-
2001
- 2001-11-29 AU AU2002221510A patent/AU2002221510A1/en not_active Abandoned
- 2001-11-29 US US10/497,287 patent/US20050084552A1/en not_active Abandoned
- 2001-11-29 WO PCT/CN2001/001591 patent/WO2003045407A1/zh not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1116545A (zh) * | 1995-04-07 | 1996-02-14 | 唐道臣 | 醒脑止痛增智粉剂 |
Non-Patent Citations (1)
Title |
---|
XU JUN ET AL.: "Pharmacology study on Chuanxiong-Baizhi(Duliang Wan)", PHARMACOLOGICAL AND CLINICAL STUDY OF CHINESE TRADIONAL MEDICINE, vol. 8, no. 3, 1992, pages 12 - 14 * |
Also Published As
Publication number | Publication date |
---|---|
US20050084552A1 (en) | 2005-04-21 |
AU2002221510A1 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091203B (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
CN105560372A (zh) | 一种治疗鼻炎的中药喷雾剂及其制备方法 | |
CN101411782B (zh) | 一种治疗急性咽炎的药物组合物及其制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN102205026A (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
CN103860978B (zh) | 一种治疗褥疮的中药制剂及其制备方法 | |
CN102671088A (zh) | 一种治疗肺结核的中药组合物 | |
CN101396528B (zh) | 一种治疗风热感冒的中药复方制剂 | |
CN105497723A (zh) | 一种治疗细菌性肺炎的中药制剂及其制备方法 | |
CN102335373A (zh) | 一种治疗上呼吸道感染的中药组合物及其制备方法 | |
WO2003045407A1 (fr) | Composition de l'herboristerie chinoise contre le rhume et le mal de tete, et son utilisation | |
CN113181336A (zh) | 一种治疗妇科疾病的中药组合物、制剂及其制备方法和应用 | |
CN103520550B (zh) | 一种治疗外寒内饮型慢性支气管炎的中药及制备方法 | |
CN105343660A (zh) | 一种治疗周围性眩晕的中药制剂及其制造方法 | |
CN111632080A (zh) | 一种治疗药疹皮炎的配方及制备方法及应用 | |
CN1327874C (zh) | 治疗慢性前列腺炎的中药制剂及其制备方法 | |
CN104173830A (zh) | 冬季感冒高烧解表和里药剂及制备方法 | |
CN103599253B (zh) | 一种用于治疗老年人冬痒症的中药组合物 | |
CN114748527B (zh) | 一种治疗婴幼儿湿疹、皮炎的复方龙胆凝胶 | |
CN106038905A (zh) | 一种麻醉止痛药物及其制备方法 | |
CN116585397A (zh) | 一种用于治疗湿疹类皮肤病的药物组合物及其制备方法和应用 | |
CN105194165A (zh) | 一种用于泌尿系统感染的中药及制备方法 | |
CN105288195A (zh) | 一种治疗甲状腺炎的药物及制备方法 | |
CN105311212A (zh) | 一种治疗慢性鼻窦炎的中药及制备方法 | |
CN117323263A (zh) | 一种具有舒缓功能的中药提取组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20018238157 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10497287 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |